Advertisement
U.S. markets open in 1 hour 26 minutes
  • S&P Futures

    5,304.50
    -3.75 (-0.07%)
     
  • Dow Futures

    40,137.00
    -7.00 (-0.02%)
     
  • Nasdaq Futures

    18,486.25
    -17.50 (-0.09%)
     
  • Russell 2000 Futures

    2,140.60
    +2.20 (+0.10%)
     
  • Crude Oil

    82.39
    +1.04 (+1.28%)
     
  • Gold

    2,229.60
    +16.90 (+0.76%)
     
  • Silver

    24.67
    -0.08 (-0.33%)
     
  • EUR/USD

    1.0789
    -0.0041 (-0.38%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.04
    +0.26 (+2.03%)
     
  • GBP/USD

    1.2616
    -0.0022 (-0.18%)
     
  • USD/JPY

    151.3610
    +0.1150 (+0.08%)
     
  • Bitcoin USD

    70,670.19
    +378.13 (+0.54%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.37
    +20.39 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

NeuroMetrix Inc (NURO) Files 10-K for the Fiscal Year Ended on December 31, 2017

- By insider

NeuroMetrix Inc (NURO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. NeuroMetrix Inc manufactures and sells wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests that help patients and physicians manage chronic pain, nerve diseases, and sleep disorders. NeuroMetrix Inc has a market cap of $3.310 million; its shares were traded at around $1.41 with and P/S ratio of 0.12.


For the last quarter NeuroMetrix Inc reported a revenue of $4.93 million, compared with the revenue of $3.72 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $17.1 million, an increase of 42.1% from last year. For the last five years NeuroMetrix Inc had an average revenue growth rate of 21.5% a year.

The reported loss per diluted share was $5.482 for the year, compared with the loss per share of $98.24 in the previous year. The NeuroMetrix Inc had an operating margin of -76.54%, compared with the operating margin of -126.44% a year before. The 10-year historical median operating margin of NeuroMetrix Inc is -125.49%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, NeuroMetrix Inc has the cash and cash equivalents of $4.04 million, compared with $3.95 million in the previous year. The company had no long term debt. NeuroMetrix Inc has a financial strength rank of 7 (out of 10).

At the current stock price of $1.41, NeuroMetrix Inc is traded at 87.5% discount to its historical median P/S valuation band of $11.26. The P/S ratio of the stock is 0.12, while the historical median P/S ratio is 0.76. The stock lost 73.37% during the past 12 months.

CEO Recent Trades:

  • President & CEO Shai Gozani bought 5,000 shares of NURO stock on 02/05/2018 at the average price of $1.48. The price of the stock has decreased by 4.73% since.

  • President & CEO Shai Gozani bought 2,000 shares of NURO stock on 02/01/2018 at the average price of $1.62. The price of the stock has decreased by 12.96% since.

  • President & CEO Shai Gozani bought 2,000 shares of NURO stock on 01/31/2018 at the average price of $1.69. The price of the stock has decreased by 16.57% since.

  • President & CEO Shai Gozani bought 1,000 shares of NURO stock on 01/29/2018 at the average price of $1.75. The price of the stock has decreased by 19.43% since.

CFO Recent Trades:

  • Senior Vice President, CFO Thomas T Higgins bought 1,000 shares of NURO stock on 02/06/2018 at the average price of $1.45. The price of the stock has decreased by 2.76% since.

  • Senior Vice President, CFO Thomas T Higgins bought 2,500 shares of NURO stock on 02/01/2018 at the average price of $1.55. The price of the stock has decreased by 9.03% since.

For the complete 20-year historical financial data of NURO, click here.

This article first appeared on GuruFocus.


Advertisement